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ABSTRACT a-Synuclein (aS) is a soluble synaptic protein that is the major proteinaceous component of insoluble ﬁbrillar Lewy
body deposits that are the hallmark of Parkinson’s disease. The interaction of aS with synaptic vesicles is thought to be critical
both to its normal function as well as to its pathological role in Parkinson’s disease. We demonstrate the use of ﬂuorescence
correlation spectroscopy as a tool for rapid and quantitative analysis of the binding ofaS to large unilamellar vesicles of various lipid
compositions. We ﬁnd that aS binds preferentially to vesicles containing acidic lipids, and that this interaction can be blocked by
increasing the concentration of NaCl in solution. Negative charge is not the only factor determining binding, as we clearly observe
binding to vesicles composed entirely of zwitterionic lipids. Additionally, we ﬁnd enhanced binding to lipids with less bulky
headgroups. Quantiﬁcation of the protein-to-lipid ratio required for binding to different lipid compositions, combined with other data
in the literature, yields an upper bound estimate for the number of lipid molecules required to bind each individual molecule of aS.
Our results demonstrate that ﬂuorescence correlation spectroscopy provides a powerful tool for the quantitative characterization of
aS-lipid interactions.
INTRODUCTION
a-Synuclein (aS) is the major ﬁbrillar component of
the Lewy body deposits in the substantia nigra that are
characteristic of Parkinson’s disease (PD) (1,2). Though the
precise role of aS in the degeneration of dopaminergic
neurons in PD remains unclear, the identiﬁcation of two
autosomal dominant mutations in aS that result in early
onset PD established that it is critical to the progression of
the disease state (3,4). More recently, a third aS mutation, as
well as triplication of the aS gene, have also been linked to
disease (5–8). a-Synuclein is a small, ;14.5 kDa, soluble
protein that is found abundantly in presynaptic nerve
terminals in various regions of the brain (9). The native func-
tion of aS is poorly understood, though it has been shown to
affect dopamine synthesis (10–12) and transport (13), and it
is thought that aS may play a role both in maintaining neu-
ronal plasticity (14) and in the regulation of synaptic vesicle
recycling (15). Despite these proposed functions, aS is only
loosely associated with either the synaptic membrane or syn-
aptic vesicles, often behaving as a soluble protein in brain
tissue extracts (1,14).
Although aS is intrinsically unstructured in solution (16),
it undergoes a conformational change to a predominantly
a-helical structure upon association with lipid membranes
(17,18). Sequence similarities between the N-terminus of aS
and the lipid-binding domains of some classes of apolipo-
proteins led to the proposal that the N-terminus mediates
aS interactions with membranes (16,18). This has been con-
ﬁrmed by NMR and EPR studies of aS bound to detergent
micelles and small unilamellar vesicles (SUVs) (19–21),
which show that the N-terminus forms an amphipathic helix
(with an unusual 11/3 periodicity) upon association with mi-
celles or vesicles, while the C-terminus remains largely free
and unstructured (20,22). It has been suggested that the
interaction of aS with membranes plays a role not only in the
normal function of the protein but also in the pathology of
PD. Speciﬁcally, studies have identiﬁed an oligomeric form
of aS that is toxic to cells in culture (23), and shown that aS
is capable of forming stable, porelike oligomers in vitro (24),
leading to the postulation that aS oligomers may be respon-
sible for permeabilization of cell membranes in the disease
state (25–27).
There have been a number of in vitro studies aimed at
elucidating the nature of the interaction of aS with mem-
branes, using model synthetic lipid vesicles as well as ex-
tracted brain tissue lipids. However, much of the existing
literature regarding these interactions is contradictory. The
majority of studies indicate that aS binds preferentially to
acidic phospholipids (17,18,28,29), though different afﬁni-
ties for speciﬁc phospholipid headgroups have been reported.
In contrast, binding of aS to zwitterionic large unilamellar
vesicles (LUVs) (30) and zwitterionic gel-phase SUVs (31)
has also been described. Adding to the debate is the question
as to whether or not association with lipids may inhibit
(29,32) or promote (29,33–35) ﬁbrillar aS formation.
The lack of general consensus regarding the nature of
aS-lipid interactions may in part be due to experimental fac-
tors, including the long timescales needed for the commonly
used techniques of gel ﬁltration and gel electrophoresis, or
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the technical constraints of thin layer chromatography (17).
Fluorescence correlation spectroscopy (FCS) allows for rapid,
equilibrium characterization of solutions of ﬂuorescently-
labeled molecules. The potential for FCS as a powerful
technique for studying the binding of peptides and proteins
to LUVs has been demonstrated by a handful of studies (36–
38). The work of Rusu et al. (37) studied the binding of a
model peptide to LUVs, to allow for comparison between the
binding parameters determined by FCS with those measured
by other techniques. Using a well-characterized peptide-lipid
system allowed them to evaluate the efﬁcacy of FCS as a
means of quantifying protein and peptide binding to phos-
pholipid vesicles.
Here we report our studies of ﬂuorescently-labeled aS
binding to LUVs using FCS. We characterize the effects of
vesicle composition and size, as well as the presence of mono-
valent and divalent ions, on the binding of aS to vesicles. In
particular, we screen for afﬁnity of aS for speciﬁc lipid
headgroups to investigate the role of charge and packing
density in determining binding.
MATERIALS AND METHODS
Protein expression and labeling
A plasmid containing a construct for wild-type aS (aS-wt) under control of
the T7 promoter was generously provided by Dr. Peter Lansbury (Harvard
Medical School). A serine-to-cysteine mutation was introduced at position 9
to allow for speciﬁc labeling of the protein (aS-S9C) using a QuikChange
Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA). Both aS-wt and
aS-S9C were expressed and puriﬁed as described previously (19). The pro-
tein aS-S9C was labeled with AlexaFluor 488 C5 maleimide dye (Molecular
Probes, Invitrogen, Carlsbad, CA) generally according to the protocol pro-
vided by the manufacturer. Alexa 488 was chosen for the ﬂuorophore based
on its photophysical properties, including photostability, high quantum yield
upon conjugation to aS, and large two-photon cross section (as character-
ized by the authors and colleagues). Brieﬂy, the aS-S9C protein was dis-
solved in pH 6.4 phosphate-buffered saline and a 25 mM stock solution of
the dye was prepared in dimethylsulfoxide and added to the protein solu-
tion to a ﬁnal molar ratio of;5:1 dye/protein. The protein-dye solution was
incubated in the dark at room temperature for a minimum of 2 h and
unreacted free dye was removed using Micro Bio-Spin 6 Chromatography
columns (Bio-Rad, Hercules, CA). The labeled protein, aS-S9C-AL488,
was passed through an additional spin column just before measurement to
remove any residual free dye. The ﬁnal protein concentrations and labeling
efﬁciency were determined by absorption.
Preparation of vesicles
All vesicle components—1-palmitoyl-2-oleoyl-phosphatidylcholine (POPC),
1-palmitoyl-2-oleoyl-phosphatidylserine (POPS), 1-palmitoyl-2-oleoyl-
phosphatidic acid (POPA), 1-palmitoyl-2-oleoyl-phosphoethanolamine (POPE),
cholesterol, egg sphingomyelin, 1,2-dioleoyl-phosphocholine (DOPC), and
1,2-dioleoyl-phosphoethanolamine lissamine rhodamine (DOPE-rhod)—
were purchased in lyophilized form from Avanti Polar Lipids (Birmingham,
AL). Stock solutions of 10 mg/ml were prepared in chloroform and stored in
sealed glass vials at 20C. Stock solutions were assayed to determine
actual concentrations before preparation of vesicles (39,40). Aliquots of the
appropriate amounts of the stock solutions were mixed in clean glass vials
and the chloroform was removed under a gentle stream of nitrogen. The
lipids were placed under vacuum for at least 4 h to ensure complete removal
of residual chloroform and then rehydrated in 50 mM sodium phosphate
buffer, pH 7.4, to a ﬁnal concentration of 2.5 or 5 mM lipid. Large
unilamellar vesicles (LUVs) were prepared by repetitive extrusion through
two layers of polycarbonate ﬁlms in a handheld extruder (Avestin, Ottawa,
Canada) (41). Vesicles were used within 2 days of preparation but were
found to be structurally stable for at least two weeks when stored at 4C. For
vesicles composed of more than one type of lipid, all percentages of lipids
are mole percentages. Unless speciﬁcally noted, LUVs refers to vesicles
formed using 100 nm polycarbonate ﬁlms.
Fluorescent vesicles were prepared by the addition of a small amount
(;1:20,000 molar ratio labeled-lipid/total lipid) of labeled lipid, DOPE-
rhod, to the stock solution.
Preparation of samples
Stock solutions of 10 mM protein were prepared of aS-S9C-AL488 and aS-
wt. The stock LUV solutions were ﬁrst diluted to the desired concentration
in 50 mM sodium phosphate buffer, pH 7.4, then aS, S9C-AL488 or wt, was
added. The samples were mixed by gently pipeting the solutions several
times and then immediately transferred to sample chambers for measurements.
Measurements were made in eight-chambered Lab-Tek cover-glass slides
(Nunc, Rochester, NY). The chambers were treated by plasma cleaning and
then incubated with polylysine-conjugated polyethylene glycol to prevent
adhesion of aS to the surfaces (42). The chambers were then incubated with
low concentrations of aqueous POPC solutions. The chambers were rinsed
thoroughly with HPLC H2O before placing the sample in the chambers.
Chambers that were not used immediately were ﬁlled with HPLC water,
which was removed just before ﬁlling chambers with sample. There was no
evidence of either vesicles or aS adsorbing to the chamber surfaces.
Principles of ﬂuorescence
correlation spectroscopy
AlthoughFCSwas inventedmore than 30 years ago (43–45), relatively recent
improvements in computation, optical, and detection technologies (46) have
made it a versatile technique that is widely used for a vast array of biochemi-
cal and biophysical characterization. The measured parameter in FCS is the
spectrum of spontaneous ﬂuctuations in ﬂuorescence intensity caused by the
changes in the emission of ﬂuorescently-labeled molecules in the optically
deﬁned focal volume due to diffusion or chemical kinetics (Fig. 1 A). The
concentration and the diffusion time of the diffusing species can be calculated
from the autocorrelation function of the ﬂuctuations. The diffusion time-
scales linearly with the hydrodynamic radius of the diffusing species.
The autocorrelation function G(t) is deﬁned as
GðtÞ ¼
*
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+
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where F(t) is the ﬂuorescence obtained from the volume at delay time t and
dF(t) ¼ F(t)  ÆF(t)æ. The autocorrelation curves are ﬁt with the standard
formula for a three-dimensional multicomponent ﬁt (47),
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where Ni is the number of molecules of species i, tDi the characteristic
diffusion time of species i, and v is the ratio of the axial/radial dimensions of
the observation volume. For a single diffusing species, i ¼ 1, the equation is
simply
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For a two-component system, such as that consisting of free aS and LUV-
bound aS, the correlation function becomes
GðtÞ ¼ 1
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where f is the fraction of the signal that comes from free aS, taS is the
characteristic diffusion time of free aS, and tLUV is the characteristic
diffusion time of the vesicles. Because of the considerable difference in size
between free aS and LUV-bound aS (Fig. 1 B), the contribution of each
species to the correlation function can easily be distinguished by ﬁtting the
experimental data to Eq. 4.
Two-photon excitation ﬂuorescence
correlation spectroscopy
FCS measurements with two-photon excitation were made on an instrument
assembled in our lab as described previously (48). Brieﬂy, a pulsed-IR
titanium-sapphire laser (Tsunami, Spectra-Physics, Palo Alto, CA) with 80
MHz, ;100-fs pulse-width was used as the excitation source, l ¼ 895 nm.
The laser was directed into a 1.2 NA, 633 objective (Zeiss, Jena, Germany)
mounted in an inverted microscope (Axiovert 35, Zeiss). The excitation
power at the objective was between 1 and 4 mW, low enough to ensure that
no photobleaching of the ﬂuorophores occurred during their residence in the
focal volume. Fluorescence emission was collected through the objective,
separated from the excitation beam with a 670-nm longpass dichroic ﬁlter
(Chroma, Rockingham, VT), and focused onto the face of a GaAsP pho-
tomultiplier tube (model No. H-7421, Hamamatsu, Somerville, NJ). The
signal from the photomultiplier was autocorrelated by a digital correlator
(ALV-6000, ALV, Langen, Germany). A typical data set consisted of 10
autocorrelation curves of 10 s each. These 10 curves were averaged and the
average curve was ﬁt according to Eqs. 3 or 4 using the standard deviation as
a weighting factor.
Rhodamine green, a dye whose diffusion parameters have been well
characterized by FCS (summarized in (49)), was measured as a calibration
standard to determine v, in Eqs. 2–4 above. Fitting autocorrelation curves of
rhodamine green gives rise to v ¼ 3.4. This value was then ﬁxed for all
subsequent ﬁtting. Steady-state ﬂuorescence (data not shown) was used
to determine a quantum yield ratio of;1 for free aS-S9C-AL488 relative to
that of LUV-bound aS-S9C-AL488, and thus there was no need for cor-
rection of the fractions of free and LUV-bound protein as determined by Eq. 4.
RESULTS
FCS measurements of free aS and dye-labeled vesicles in
separate experiments were used to determine their individual
diffusion times. Fig. 1 B shows the autocorrelation curves of
aS-S9C-AL488 and DOPE-rhod-labeled vesicles, as well as
a curve with both free and LUV-bound aS-S9C-AL488 com-
ponents. The curves for free aS and the LUVs were ﬁt to Eq.
3, resulting in diffusion times of;250 ms for the protein and
;3.8 ms for the vesicles. Both curves were well ﬁt to single-
component equations indicating monodisperse solutions.
The corresponding hydrodynamic radius of ;60 nm, or
diameter of ;120 nm, calculated for the vesicles is within
the reported range of diameters for vesicles formed by ex-
trusion through 100 nm pores. We saw some small variations
in tLUV, depending upon the composition of the vesicles and
the amount of protein bound; thus for the ﬁtting of auto-
correlation curves of solutions containing both free aS and
LUV-bound aS using Eq. 4, taS was ﬁxed to 250 mS, while
tLUV was allowed to ﬂoat to obtain the best ﬁt for the data.
The placement of the Alexa 488 label was carefully
chosen based on NMR-derived models of aS-micelle and
aS-SUV interactions (20) to minimize possible disruption of
protein-lipid interactions, and prior NMR studies conﬁrmed
that the S9C mutation does not signiﬁcantly perturb the
structure of detergent micelle-bound aS (22). Nevertheless,
the possibility remained that the dye would affect—either
negatively or positively—the binding of aS to the vesicles.
To control for this, we made three samples containing 100%
POPS LUVs with a ﬁxed overall concentration of aS, but
with varying relative amounts of aS-S9C-AL488 and aS-wt.
The normalized autocorrelation curves (Fig. 2) are virtually
indistinguishable, and ﬁtting of the curves yields a fraction
LUV-bound protein of ;0.8 for all three cases (Table 1).
FIGURE 1 (A) Cartoon depicting the optically deﬁned focal volume of an
FCS instrument. Fluctuations in the intensity of the ﬂuorescence signal result
from the diffusion of the ﬂuorescent molecules—shown here as free protein
and LUV-bound protein—in and out of the focal volume. (B) Autocorre-
lation curves of aS only (black) and LUV only (light gray) are ﬁt to Eq. 3
(ﬁts in red); the autocorrelation curve of a mixture of free aS and LUV-
bound aS (dark gray) is ﬁt to Eq. 4 (ﬁt in blue) to yield 60% LUV-bound aS
and 40% free aS. The free aS has a diffusion time of;250 ms and the;120
nm LUVs have a diffusion time of ;3.8 ms, ;15 times longer than that of
the free protein. This difference in diffusion times allows for separation of
the contribution of each type of molecule in a mixed solution to the auto-
correlation curve.
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Therefore, the wild-type and dye-labeled proteins appear to
bind to the vesicles equally well. We also measured solutions
of free Alexa 488 dye mixed with high (mM) concentra-
tions of POPC and POPS LUVs and found no evidence of
interactions of the free dye with the LUVs, as seen by auto-
correlation curves that ﬁt to a single diffusing component
identical to that of free Alexa 488 dye in buffer (data not
shown).
Because of signiﬁcant experimental evidence that the
presence of acidic phospholipid increases binding of aS to
vesicles, 100% POPS LUVs were used for initial character-
ization of lipid binding by aS. Shown in Fig. 3 A are
autocorrelation curves for a ﬁxed amount of lipid (25 mM), a
ﬁxed amount of aS-S9C-AL488 (25 nM), and increasing
amounts of aS-wt to increase the overall concentration of
aS. FCS data were collected at each concentration of protein,
and the autocorrelation curves were ﬁt to Eq. 4 to yield the
relative amounts of LUV-bound and free aS. For the initial
data points where the concentration of aS is low, almost all
of the protein is bound to the vesicles, but as the concen-
tration of protein is increased past saturation, increasing
amounts of free protein are found in the solution (Fig. 3 A,
inset). This is shown not only by the ﬁtting results, which
indicate a decreasing fraction of LUV-bound protein, but
also by the decrease in G(0), which is inversely proportional
to the average number of molecules in the focal volume, with
increasing aS.
Surprisingly, when the data from Fig. 3 A, inset, are
plotted as the concentration of LUV-bound protein versus
the total protein concentration (Fig. 3 B), it becomes apparent
that above a certain total protein concentration (;500 nm in
this case) the concentration of LUV-bound protein starts to
decrease instead of remaining constant as expected. The max-
imum amount of LUV-bound protein is observed at a protein/
lipid mol ratio of ;1:45. At higher protein concentrations,
more lipids are required per bound protein molecule. This is
inconsistent with the saturation of a ﬁxed number of protein
binding sites on the lipid vesicles, and suggests instead
that binding sites are eliminated at high protein/lipid ratios.
a-Synuclein has been reported to destabilize lipid bilayers,
and it may be that such an effect is responsible for these
observations.
To investigate the role of the negatively charged lipids in
binding, LUVs composed of various ratios of zwitterionic
FIGURE 2 Autocorrelation curves of solutions with three different ratios
of aS-S9C-AL488 and aS-wt for the same total concentration aS. (A) 200
nM aS-S9C-AL488 and 200 nM aS-wt. (B) 100 nM aS-S9C-AL488 and
300 nM aS-wt. (C) 50 nM aS-S9C-AL488 and 350 nM aS-wt. The ﬁts to
Eq. 4 of the three curves are shown in red. The curves are normalized to a
G(0) ¼ 1 to allow for comparison of the data.
TABLE 1 Fraction of bound aS for each of the aS
combinations shown in Fig. 2
Sample aS-S9C-AL488 aS-wt Fraction bound
A 250 nM 150 nM 0.796 6 0.04
B 100 nM 300 nM 0.823 6 0.035
C 25 nM 375 nM 0.784 6 0.062
FIGURE 3 (A) Autocorrelation curves of solutions with increasing
concentration of aS with 25 mM 100% POPS LUVs. The concentrations
of aS shown are: 50 nM (squares), 200 nM (circles), 400 nM (triangles),
500 nM (inverted triangles), 750 nM (diamonds), 1 mM (cross-hairs), and
1.5mM (pentagons) (the last three concentrations are difﬁcult to differentiate
on this plot). (Inset) The curves in panel A were ﬁt with Eq. 4 to determine
the fraction of free and bound aS. Increasing the aS concentration beyond
saturation results in a decrease in the fraction of bound protein. (B). The data
in Fig. 4 A, inset, is replotted as LUV-bound aS as a function of total aS.
Above ;500 nM total aS, the total amount of bound protein begins to
decrease instead of remaining constant as may be expected.
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POPC and acidic POPS were prepared. For each LUV com-
position, FCS data were collected at increasing LUV con-
centrations, while maintaining a constant aS concentration
(200 nM), and the autocorrelation curves were ﬁt to Eq. 4 to
yield the relative amounts of LUV-bound and free aS. The
fraction of LUV-bound protein calculated from FCS data
was plotted as a function of the accessible lipid con-
centration, which is estimated to be half of the total lipid
concentration, because it is assumed that aS cannot access
the lipid of the interior of the vesicles. The data (Fig. 4 A)
show that aS binds much more readily to LUVs containing a
higher percentage of negatively charged lipids, in agreement
with the majority of other in vitro lipid-binding studies. The
binding curves are not hyperbolic and could not be well ﬁt
based on a simple partition equilibrium model. Data points
collected at low lipid concentrations may be affected by the
high protein/lipid ratio, as observed above, and may be
partially responsible for the apparent lag in protein binding.
This effect has also been noted in a recent study using
calorimetry to monitor the binding of aS to SUVs (31). This
same study also noted that electrostatic interactions between
the protein and the lipid vesicles lead to deviations from a
simple partition equilibrium. Both of these effects might be
expected to be mitigated at lower protein concentrations, but
binding curves from data collected at a 10-fold lower con-
centration of aS (20 nM) showed the same shape and were
also poorly ﬁt by the partition equilibrium model (data not
shown).
Reasonable ﬁts to the binding curves could be obtained
using the Hill equation and yielded apparent disassociation
constants, KD, for the various lipid compositions (Fig. 4 B).
Similar KD values were obtained either from best ﬁts to a
simple partition equilibrium or from 50% binding values
extracted from best ﬁts to a dose-response model. The ap-
parently exponential relationship between KD and the frac-
tion of acidic lipid is predicted by Boltzmann and electrostatic
theory (50). The value of the Hill coefﬁcient obtained from
the binding curves was ;2.4, but it is not clear how to
interpret this value.
To further examine the role of charge-charge interactions
in the binding of aS to lipids, increasing amounts of NaCl
were added to a ﬁxed amount of LUV and aS-S9C-AL488.
As the concentration of NaCl was increased from 0 to
400 mM, the fraction of LUV-bound aS decreased (Fig. 5),
showing that high salt concentrations inhibit lipid binding by
aS. We also investigated the ability of the divalent ion cal-
cium to disrupt aS-vesicle interactions. Due to the mutual
insolubility of phosphate and calcium, the LUVs were made
in 20 mM MOPS buffer, pH 7.4, rather than the standard
phosphate buffer. Amounts of up to 20 mM CaCl2, well
above the physiologically relevant concentrations, had no
effect on the binding of aS to the vesicles (data not shown).
The strong preference of aS for acidic phospholipids, as
well as the decrease in its binding to 100% POPS vesicles
with increasing NaCl concentrations, demonstrates the
FIGURE 4 (A) Fraction aS bound as a function of lipid concentration for
ﬁve different vesicle compositions. The concentration of aS was maintained
at 200 nM, whereas the concentration of lipid was increased. The fraction aS
bound was calculated from ﬁtting Eq. 4 to the autocorrelation curves for
each concentration of lipid: 100% POPS (circles), 70% POPS/30% POPC
(triangles), 50% POPS/50% POPC (squares), 30% POPS/70% POPC
(diamonds), and 100% POPC (inverted triangles). Also shown is the binding
curve for ;60 nm diameter 100% POPS vesicles (solid circles). The ﬁts
shown in shaded representation are to the Hill equation, which yields a Hill
coefﬁcient 2.4 and a KD for each composition of lipids. (B) The log of KD
as determined from the ﬁts of the Hill equation to binding curves shown in
panel A as a function of molar percentage POPS.
FIGURE 5 Fraction aS bound to 100% POPS LUVs as a function of
NaCl concentration, with 200 nM aS. Increasing concentration of NaCl
results in screening of the favorable electrostatic interactions between aS
and the vesicles, and thus a decreasing fraction of bound protein.
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importance of electrostatics in this interaction. However,
binding to neutral POPC vesicles was also clearly observed
and indicates that nonelectrostatic interactions are also in-
volved. To investigate possible preferences of aS for speciﬁc
phospholipid headgroups, three different combinations of
acidic and zwitterionic lipids, each in a 1:1 molar ratio, were
characterized at three different aS-S9C-AL488/lipid ratios
(Fig. 6). Under conditions where less than half of the aS is
bound to POPS/POPC, nearly 100% of the aS was bound
to the POPA/POPC vesicles. The fraction of LUV-bound
aS was also slightly higher for POPS/POPE vesicles than
for POPS/POPC vesicles, indicating a preference for this
composition—although the difference was much smaller
than that observed for the POPA/POPC vesicles.
Because curvature has been suggested to play an impor-
tant role in binding of aS to lipids (18), 100% POPS vesicles
were prepared using polycarbonate membranes with a 50-nm
pore size. The measured diffusion time corresponds to ves-
icles with a diameter of ;60 nm, or approximately one-half
the diameter of the larger LUVs. The fraction of aS bound as
a function of total accessible lipid for these vesicles is very
close to the data obtained using the 120 nm 100% POPS
LUVs (solid and open circles in Fig. 4 A, respectively),
indicating no substantial preference on the part of aS for the
more highly curved surface of the smaller vesicles.
Lastly, synaptic vesicles contain a high proportion of
sphingomyelin and cholesterol, suggesting a propensity for
phase heterogeneity in the membrane, a phenomenon that is
thought to underlie the formation of raft domains in cellular
membranes. Several recent articles have indicated localiza-
tion of aS to lipid rafts in cells (51) or binding of aS with
LUVs containing raft-associated components (52,53). Thus,
we prepared LUVs corresponding to the canonical raft
mixture of 1:1:1 molar ratio DOPC/sphingomyelin/choles-
terol, which mimics the composition of the outer leaﬂet of
the plasma membrane (54), as well as 100% DOPC LUVs. In
both cases, the vesicles are electrostatically neutral. The frac-
tion of LUV-bound aS for both types of LUVs was sta-
tistically indistinguishable from that found for 100% POPC
vesicles (data not shown).
DISCUSSION
Using FCS to monitor aS-vesicle interactions
Although several other studies have established that FCS can
be a powerful method for analyzing peptide and protein
binding to LUVs (36–38), a primary goal of this study was to
demonstrate the utility of FCS for quantifying binding of
aS to lipid vesicles. FCS has several advantages over the
techniques that have commonly been used to characterize
aS-lipid interactions. A series of autocorrelation curves that
allows for statistical analysis of the binding behavior can be
collected within 2–3 min of ﬁrst mixing the protein and
vesicles together. This is in direct contrast to more traditional
methods such as chromatography, where the protein and
vesicles may spend several hours traversing a column or gel,
or ultracentrifugation, which also requires several hours.
FCS is also applicable over a wide range of ﬂuorophore
concentrations, from nM to mM. For most of the experiments
presented in this article, a ﬁxed concentration of 200 nM aS-
S9C-AL488 was used. However, the data shown in Fig. 3
were measured with 25 nM aS-S9C-AL488, and binding
measurements using as little as 5 nM aS-S9C-AL488 were
also performed (data not shown). This is between 100 and
1000 times lower protein concentration than is required for
other techniques, such as circular dichroism (CD), chroma-
tography, and calorimetry. Furthermore, as demonstrated in
Fig. 3, the upper end of the range of protein concentrations
can be extended almost indeﬁnitely by maintaining the
amount of ﬂuorescently-labeled protein within the desired
nM–mM range and adding unlabeled protein to achieve the
desired ﬁnal protein concentration, so long as the binding
properties of the labeled and unlabeled proteins are the same
(as we show to be the case here in Fig. 2).
CD is used to detect the binding of aS to lipids via
the appearance of spectral lines associated with a-helical
secondary structure (18), but quantitative interpretation of
the results may not be straightforward. For example, a study
by Jo et al. (17) found that although thin layer chromatog-
raphy indicated binding of aS to POPE, POPE did not
induce a-helical structure in aS as detected by CD unless an
acidic lipid was also present. In another example, Narayanan
and Scarlata (30) reported that interaction of aS with 100%
POPS LUVs did not induce signiﬁcant amounts of a-helical
structure in aS according to their CD data. However, at aS
concentrations above the saturating concentration, the
primary component of the CD spectra comes from random-
coil free aS with only a minor contribution arising from the
small population of a-helical LUV-bound aS. In contrast,
interpretation of binding data from FCS is straightforward,
FIGURE 6 Comparison of fraction aS bound for three different combi-
nations of lipids, with 200 nM aS. Each combination consists of a
zwitterionic lipid and an acidic lipid in a 1:1 molar ratio: POPA/POPC
(triangles), POPS/POPE (squares), and POPS/POPC (circles). The protein
shows much stronger binding to the POPA/POPC and slightly stronger
binding to POPS/POPE when compared to the POPS/POPC LUVs.
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because the signals from the free aS and LUV-bound aS are
both detectable and separable, as well as being independent
of secondary structure formation.
Lipid-binding properties of aS
Our data reveal a marked preference by aS for binding to
acidic phospholipids (Fig. 4), consistent with a number of pub-
lished studies. We also conﬁrm that electrostatic interactions
are important for aS-lipid binding, because physiological ex-
tracellular NaCl concentrations result in a considerable de-
crease, although not complete elimination, of the amount of
aS bound to LUVs (Fig. 5). However, the data indicates a
signiﬁcantly higher afﬁnity for vesicles composed of some
portion of POPA over those containing an equivalent amount
of POPS, as well as a slightly higher afﬁnity for POPE over
POPC (Fig. 6). Because both POPA and POPS are neg-
atively charged and both POPE and POPC are zwitterionic, it
appears that aS is sensitive to lipid headgroup properties
beyond total charge. At pH 7.4, some percentage of POPA
headgroups will have a valence of 2 (average relative
charge ;1.2 for POPA versus 1 for POPS at pH 7.4
(55)), which may partially account for the greater afﬁnity of
aS for POPA. In addition, POPA is lacking in the bulky
amino-serine group of POPS, and might therefore be able to
pack more closely together in a lipid bilayer, producing a
higher charge density. Alternatively, the bulkier POPS head-
group may interfere sterically with aS binding. Several other
studies have noted a preference for binding to POPA over
POPS (18,28,56). This preference may be biologically rel-
evant, because aS has been shown to regulate the activity of
phospholipase D, an enzyme that produces PA from PC, and
furthermore PA is a regulator of synaptic vesicle biogenesis,
a process that may be affected by aS. However, it has also
been pointed out that PS comprises ;7–12% of the total
lipid in synaptic vesicles where aS localizes, whereas PA is
only ;0–2% (18).
Our data provide a direct quantitation of the binding of aS
to lipid vesicles. Fig. 3 B suggests that for POPS, the maxi-
mum achievable molar ratio of bound protein to total lipid is
;1:85, corresponding to a weight ratio of bound protein to
total lipid of;1:5. The POPS data in Fig. 4 A also show that
complete protein binding can occur at a protein/total lipid
molar ratio of ;1:100. For 1:1 POPA/POPC vesicles, Fig. 6
shows that complete binding can occur at a protein/lipid
molar ratio of;1:250. For 1:1 POPS/POPC, however, Fig. 4
A indicates that complete protein binding occurs at protein/
lipid molar ratio of;1:2000, corresponding to a weight ratio
of bound protein to total lipid of ;1:100. However, it is
important to note that this number merely provides an upper
bound on the number of lipid molecules required to bind
each aS molecule, since, in these experiments, the protein
concentration is held ﬁxed and might not be high enough to
saturate every binding site. It is instructive to compare these
results with other published work. An early study of aS
lipid binding showed, using ultracentrifugation, that for 1:1
POPA/POPC vesicles, a 1:20 protein/lipid weight ratio (cor-
responding to a molar ratio of;1:370) sufﬁced for complete
protein binding, but the same ratio of protein to 1:1 POPS/
POPC vesicles was insufﬁcient for complete binding (18).
These results are in good agreement with our own. Another
early study reported that for 1:1 POPS/POPC vesicles, a
protein/lipid weight ratio of 1:10 (corresponding to a molar
ratio of ;1:185) was sufﬁcient for complete protein binding
as determined by CD data (17). A similar result was obtained
for 1:1 POPG/POPC vesicles by another group (31). These
studies were performed at higher protein concentrations
(;10 mM) than our own (;200 nM), and this may account
for the lower observed number of lipid molecules per bound
protein molecule. In total, our results combined with those of
others suggest that each molecule of aS can bind to a lipid
bilayer patch composed of #85 acidic lipid molecules.
Dilution of acidic lipids with neutral lipids signiﬁcantly re-
duces the afﬁnity of aS for the lipid surface but appears
unlikely to alter the number of lipids bound per aS molecule.
These conclusions can be evaluated in the context of our
knowledge of the structure of lipid-bound aS. The protein
binds to lipid surfaces through a highly helical conformation
adopted by the N-terminal ;100 residues, while the acidic
C-terminal tail of the protein remains free. A 100-residue
helix would be ;15-nm long and 1-nm wide, and would
therefore cover a surface area of 15 nm2. In comparison, an
individual lipid molecule in a bilayer occupies ;0.5 nm2 of
surface area. Therefore, a minimum of 30 surface-accessible
lipid molecules, or a 60-molecule bilayer patch, would be
required to bind a single aS molecule. Our data indicate
that ;1.5 times this minimum number of lipid molecules is
actually required per aS molecule and that trying to force a
higher aS/lipid ratio may result in destabilization of the lipid
bilayer. Interestingly, aS oligomers have been reported to
permeabilize phospholipid vesicles (26), and this has been
proposed as a general mechanism of toxicity for amyloid-
forming proteins (57). It is possible that in the absence of
sufﬁcient lipid surface area, aS oligomerization may be
facilitated (this has been referred to as the parking-problem)
leading to lipid bilayer disruption. Such a mechanism might
also provide a partial explanation for the cooperativity ob-
served in the binding curves of Fig. 4. However, we do not
have any direct evidence for such a mechanism at present.
Finally, our preliminary examination of the interaction of
aS with vesicles containing cholesterol and sphingomyelin
shows that aS exhibits the same binding afﬁnity for vesicles
composed of a raft mixture of lipids as for 100% DOPC
vesicles, suggesting that it is the presence of negatively
charged components—either protein/peptide or phospholi-
pids—in the raft domain of the membrane, rather than any
physical property of the lipid phase itself that inﬂuences the
binding of the protein. Nuscher et al. (31) characterized the
binding of aS to neutral gel phase SUVs and attributed
the binding afﬁnity both to the high curvature of the SUVs
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and to the formation of lipid phase domains within the
vesicles. It is therefore possible that further binding studies
using gel phase or liquid-ordered phase SUVs, instead of the
LUVs examined here, would reveal a higher propensity for
aS binding. Because of the possible physiological relevance
of the raft membrane composition, this remains an avenue
for further exploration. It is possible that small changes in the
proportions of the lipid components may result in dramatic
differences in membrane heterogeneity and thus drastically
affect aS binding. FCS provides a rapid, quantitative means
of characterizing these interactions.
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